The stock of Hikma Pharmaceuticals Plc (LON:HIK) is a huge mover today! The stock decreased 4.24% or GBX 74.71 on November 10, hitting GBX 1689.29. About 1.78M shares traded hands or 153.46% up from the average. Hikma Pharmaceuticals Plc (LON:HIK) has declined 19.23% since April 13, 2016 and is downtrending. It has underperformed by 24.88% the S&P500.
The move comes after 7 months positive chart setup for the GBX 4.06B company. It was reported on Nov, 10 by Barchart.com. We have GBX 2466.36 PT which if reached, will make LON:HIK worth GBX 1.87B more.
Hikma Pharmaceuticals Plc (LON:HIK) Ratings Coverage
Out of 14 analysts covering Hikma Pharmaceuticals PLC (LON:HIK), 13 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 93% are positive. Hikma Pharmaceuticals PLC has been the topic of 90 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Morgan Stanley maintained the stock with “Equal Weight” rating in Friday, August 12 report. The company was maintained on Tuesday, August 16 by JP Morgan. Jefferies maintained Hikma Pharmaceuticals Plc (LON:HIK) on Monday, November 2 with “Buy” rating. The stock of Hikma Pharmaceuticals Plc (LON:HIK) earned “Overweight” rating by JP Morgan on Wednesday, June 1. The stock of Hikma Pharmaceuticals Plc (LON:HIK) earned “Overweight” rating by JP Morgan on Monday, March 14. The rating was maintained by Jefferies with “Buy” on Tuesday, July 26. The firm earned “Overweight” rating on Tuesday, October 27 by JP Morgan. The firm has “Overweight” rating by JP Morgan given on Monday, February 29. The company was maintained on Wednesday, February 10 by J.P. Morgan. The company was maintained on Tuesday, July 5 by Jefferies.
More news for Hikma Pharmaceuticals Plc (LON:HIK) were recently published by: Fool.Co.Uk, which released: “Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after …” on August 24, 2016. Fool.Co.Uk‘s article titled: “Hikma Pharmaceuticals plc set for FTSE 100 re-entry and Inmarsat plc for ejection” and published on May 27, 2016 is yet another important article.
Hikma Pharmaceuticals Plc is a pharmaceutical company. The company has a market cap of 4.06 billion GBP. The Firm develops, makes and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa region and Europe. It has a 24.95 P/E ratio. The Company’s divisions include Branded, Injectables, Generics and Others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.